Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2024 Earnings Call Transcript March 4, 2025 Rigel Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.8, expectations were $0.3.

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) is set to release its Q4 2024 earnings on March 4, 2025.The consensus estimate for Q4 2024 revenue is $51.73 million, and the earnings are expected to come ...

These increases were partially offset by decreased research and development costs due to the timing of clinical trial activities related to R289, Rigel's dual IRAK 1/4 inhibitor program ...